Liquidia (NASDAQ:LQDA) Given “Buy” Rating at HC Wainwright

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $29.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 89.30% from the company’s current price.

A number of other research analysts also recently weighed in on LQDA. Scotiabank reissued an “outperform” rating on shares of Liquidia in a research note on Monday, May 5th. Needham & Company LLC restated a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a report on Thursday, April 10th. Finally, Raymond James raised their price objective on Liquidia from $27.00 to $29.00 and gave the company a “strong-buy” rating in a report on Friday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Liquidia currently has an average rating of “Buy” and an average price target of $27.13.

Liquidia Stock Down 0.2%

Shares of LQDA opened at $15.32 on Monday. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.81. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.40 and a beta of 0.24. The stock’s 50-day moving average price is $14.25 and its 200 day moving average price is $13.18.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. Equities research analysts expect that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 2,450 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the transaction, the insider now directly owns 263,152 shares of the company’s stock, valued at $3,597,287.84. This represents a 0.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jason Adair sold 1,856 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares of the company’s stock, valued at approximately $2,501,005.28. This trade represents a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,138 shares of company stock valued at $450,233. 26.50% of the stock is currently owned by insiders.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the company. Hurley Capital LLC purchased a new stake in shares of Liquidia during the 1st quarter valued at $32,000. GAMMA Investing LLC raised its position in Liquidia by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after purchasing an additional 1,173 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in Liquidia in the 4th quarter worth $59,000. Summit Investment Advisors Inc. grew its holdings in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. bought a new stake in Liquidia in the 4th quarter worth $142,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).